Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.4K
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026
Same author

Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers.

medRxiv : the preprint server for health sciences·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis.

Blood advances·2026
Same author

Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.

Cancer cell·2026
Same author

Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.

Clinical genitourinary cancer·2026

Related Experiment Video

Updated: Mar 29, 2026

Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.9K

USING SOMATIC MUTATION DATA TO TEST TUMORS FOR CLONAL RELATEDNESS.

Irina Ostrovnaya1, Venkatraman E Seshan1, Colin B Begg1

  • 1Memorial Sloan Kettering Cancer Center.

The Annals of Applied Statistics
|November 24, 2015
PubMed
Summary

Distinguishing cancer metastasis from new primary tumors is challenging. This study introduces a novel statistical method to assess clonal relatedness between tumor pairs, aiding accurate diagnosis.

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Experiment Videos

Last Updated: Mar 29, 2026

Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.9K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Area of Science:

  • Oncology
  • Pathology
  • Biostatistics

Background:

  • Determining if a new tumor is a metastasis or independent primary cancer is a critical challenge in oncology.
  • Previous methods for assessing tumor relatedness focused on genetic markers like loss of heterozygosity and copy number profiles.
  • The advent of gene sequencing for point mutation analysis in tumors presents new challenges for determining clonal origin.

Purpose of the Study:

  • To address the methodological difficulties in comparing mutational profiles of paired tumors.
  • To propose and evaluate a new statistical test for assessing clonal relatedness between two tumors from the same patient.

Main Methods:

  • Development of a statistical test specifically designed for comparing point mutation profiles in paired tumor specimens.
  • Utilizing simulations to assess the properties and performance of the proposed clonality test.
  • Application of the method to real-world examples from existing literature.

Main Results:

  • The proposed statistical test for clonal relatedness demonstrated promising properties in simulation studies.
  • The method provides a framework for analyzing complex mutational profiles from next-generation sequencing data.
  • Illustrative examples show the practical utility of the test in pathological assessments.

Conclusions:

  • The developed statistical test offers a valuable tool for pathologists to differentiate between metastatic and independent primary tumors.
  • Accurate determination of tumor origin can significantly impact patient treatment strategies.
  • This work advances the statistical methodologies available for cancer subtyping and clonal analysis.